Tarextumab Antibody

Tarextumab (OMP-59R5) is a fully human IgG2 monoclonal antibody that selectively inhibits Notch2 and Notch3 receptors. Preclinical and clinical evidence supports its efficacy in epithelial cancers like pancreatic, lung, and ovarian cancer, making it a promising candidate for oncology research. Its utility extends to in vitro signaling studies and in vivo tumor model experiments.